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A wider application of living donor liver transplanta-
tion is limited by donor morbidity concerns. An ob-
servational cohort of 760 living donors accepted for
surgery and enrolled in theAdult-to-Adult LivingDonor
Liver Transplantation cohort study provides a compre-
hensive assessment of incidence, severity and natu-
ral history of living liver donation (LLD) complications.
Donor morbidity (assessed by 29 specific complica-
tions), predictors, time fromdonation to complications
and time from complication onset to resolution were
measured outcomes over a 12-year period. Out of the
760 donor procedures, 20 were aborted and 740 were
completed. Forty percent of donors had complications
(557 complications among 296 donors), mostly Clavien
grades 1 and 2. Most severe counted by complication
category; grade 1 (minor, n = 232); grade 2 (possibly
life-threatening, n = 269); grade 3 (residual disability,
n = 5) and grade 4 (leading to death, n = 3). Hernias
(7%) and psychological complications (3%) occurred
>1 year postdonation. Complications risk increased
with transfusion requirement, intraoperative hypoten-
sion and predonation serum bilirubin, but did not de-
cline with the increased center experience with LLD.
The probability of complication resolution within 1
yearwas overall 95%, but only 75% for hernias and 42%
for psychological complications. This report compre-
hensively quantifies LLD complication risk and should
inform decision making by potential donors and their
caregivers.
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Introduction
Broader application of living donor liver transplants (LDLT),
particularly for adult recipients, requires a comprehensive
assessment of donor risk. One of the primary goals of
the Adult-to-Adult living donor liver transplantation cohort
study (A2ALL) was to analyze the incidence and signifi-
cance of living liver donor (LLD) complications in a multi-
center cohort of United States (US) transplant centers. It
was felt that a comprehensive compilation of pre-, intra-
and postdonation clinical parameters would allow for anal-
yses that would inform an assessment of risk.
We previously published the complications in a retrospec-
tive A2ALL cohort of LLD (1). Prospective enrollment of
an observational A2ALL cohort by the same participat-
ing centers is now complete, allowing us to answer sev-
eral questions: (1) has the incidence and severity of LLD
complications changed over time? (2) are there new or
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different risk factors associated with postdonation com-
plications that were not previously identified? (3) should
future data collection on the risk of LLD complications be
more focused? and (4) does longer follow-up yield relevant
data on late-onset LLD complications or insight into reso-
lution of complications once they occur? The current study
was designed to address each of these questions.
Methods
Study design and cohort era definitions
The A2ALL consortium includes nine US transplant centers, and collected
data on subjects evaluated at these centers for LLD between 1/1/98 and
8/31/09, with follow-up extending through 8/31/10. Subjects included in this
report were accepted for donation and went to the operating room with the
intention to donate. Data on potential donors undergoing evaluation on or
before 2/28/03 were collected retrospectively (retrospective era). At initia-
tion of the prospective study, retrospective era potential or actual donors
were invited to enroll for prospective follow-up from that point forward. For
the subset that could not be contacted for consent, data were updated in
2008 under a waiver of consent. Among the retrospective era donors, 22%
of the total postdonation follow-up time was prospective. Those who under-
went evaluation for donation between 2/28/03 and the date of site initiation
(bridge donors) were also invited to enroll in ongoing prospective follow-up,
along with those who were evaluated after study site initiation (prospective
donors); 23% of postdonation follow-up time in this cohort (bridge donors
+ prospective donors = prospective era) was retrospective, and 77% was
prospective. Median postdonation follow-up was 3.4 years (retrospective
era; range [0–10.4 years]) and 1.8 years (prospective era; range [0.01–6.9
years]). Data on 29 specific complications were collected for each donor. For
each recorded complication, information required for Clavien grading (2–4)
(Table 1) and the dates of onset and resolution were recorded. Previously
published data from the retrospective era (1) were updated for complication
occurrences, Clavien grade and time to resolution.
Statistical methods
Donor and intraoperative characteristics are presented using descriptive
statistics. Complications were tabulated by type and grade, using the high-
est grade for donorswithmultiple complications. The Kaplan–Meiermethod
was used to estimate the unadjusted probability of complications by time
since donation, and the probability of resolution of complications by time
since complication onset, censored at the earliest of last known follow-up
or death. The log-rank test was used to compare complication probabilities
between those enrolled in the retrospective and prospective eras. Multi-
variable Cox regression models were fitted to identify significant predictors
of complication risk and time to resolution; covariate effects are expressed
as estimated hazard ratios (HR), and 95% confidence intervals (CI). Co-
variates tested (all measured at the time of donation) included donor age,
sex, ethnicity, race, height, weight, BMI, relatedness to recipient, alkaline
phosphatase level, total bilirubin level, donated lobe (left vs. right), remnant
liver weight, ratio of remnant to original liver volume, amount of transfused
blood, intraoperative hypotension, length of operation, year of donation and
center-specific experience with living donation (defined as sequential donor
case number at each center). In addition, three measures of liver regen-
eration by 3 months (absolute growth, percentage growth and percentage
regeneration) were individually tested in Cox models as possible predictors
for the following outcomes beyond 3 months: any complication, bile leak,
infection and hernia. All analyses were carried out using SAS 9.2 statistical
software (SAS Institute Inc., Cary, NC, USA).
Human subjects protection
The study was approved by the Institutional Review Boards of the Uni-
versity of Michigan Data Coordinating Center and each of the A2ALL
programs.
Results
Baseline and intraoperative donor characteristics
Among the 1870 potential LLDs evaluated across the en-
tire observational cohort (retrospective and prospective),
760 went to the operating room with an intention to
donate, 740 underwent complete donation and 738/740
grafts were transplanted into the intended recipient. There
were 707 right lobe and 33 full left lobe donations. Pre-
operative characteristics are shown in Table 2A for the
740 donors by era of donation (retrospective, n = 408;
prospective, n = 352). Given the absence of any impor-
tant differences between eras (only alkaline phosphatase
levels were different [p < 0.0001] but 96% were below
Table 1: Clavien system for classification of negative outcomes in general surgery and solid organ transplantation (2–4)
grade 1 Any alteration from ideal postoperative course with complete recovery or which can be easily controlled and which
fulfills the general characteristics:
a) Not life-threatening.
b) Not requiring use of drugs other than immunosuppressive agents, analgesics, antipyretic, anti-inflammatory and
antiemetic, drugs required for urinary retention or lower urinary tract infection, arterial hypertension, hyperlipidemia
or transient hyperglycemia.
c) Requiring only therapeutic procedures that can be performed at the bedside.
d) Postoperative bleeding requiring ≤3 units of blood.
e) Never associated with a prolongation of ICU stay or total hospital stay to more than twice the median stay for the
procedure in the population of the study.
grade 2 Any complication that is potentially life-threatening or results in ICU stay ≥5 days, hospital stay ≥4 weeks for the
recipient or ≥2 weeks for the donor, but which does not result in residual disability or persistent diseases.
grade 3 Any complication with residual or lasting functional disability or development of malignant disease.
grade 4 Complications that lead to transplantation (grade 4a) or death (grade 4b)
ICU = intensive care unit.
Grades were calculated by checking criteria from highest to lowest grade. Any reported complication that did not meet grade 2–4 criteria
was considered to be grade 1. In particular, criteria 1(b) through 1(e) were not necessarily applied due to potential inconsistencies with
criteria for higher grades. For example, in the A2ALL, median ICU stay was 1 day, and median hospital stay was 3 days; using criterion
(e), an ICU stay of 4 days would exceed the criteria for grade 1 but not meet criteria for grade 2.
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Table 2A: Characteristics of adult LLD candidates who went to the operating room with the intention to donate
Retrospective Era donors (N = 408) Prospective Era donors (N = 352)
Characteristic N Range Mean (s.d.) or percent N Range Mean (s.d.) or percent
Age at donor evaluation 408 18–59 37(10) 352 20–63 38(10)
Sex
Male 227 56% 173 49%
Female 181 44% 179 51%
Ethnicity
Hispanic/Latino 76 18% 47 13%
Nonhispanic/Nonlatino 331 82% 305 87%
Missing 1 0
Race
White 367 90% 324 92%
African–American 15 4% 11 3%
Asian 13 3% 5 1%
Other 12 3% 12 3%
Missing 1 0
Height (cm) 402 150–203 172 (10) 350 135–196 172 (10)
Weight (kg) 407 43–141 78 (15) 345 44–135 78 (16)
Body mass index (kg/m2) 402 17–43 26 (4) 344 16–42 26 (4)
BMI < 20 19 5% 8 2%
20 ≤ BMI < 25 136 33% 130 38%
25 ≤ BMI < 30 183 46% 150 44%
BMI ≥ 30 64 16% 54 16%
Missing 6 8
Relatedness to recipient
Biologically related
Parent 9 2% 17 5%
Child 141 35% 121 35%
Sibling 93 23% 64 18%
Other biological 34 8% 27 8%
Not biologically related
Spouse 52 13% 28 8%
Other nonbiological 78 19% 92 26%
Unknown/Missing 0 3
Alkaline phosphatase1 (IU/L) 407 21–197 75 (26) 350 15–179 65 (20)
Alkaline phosphatase ≤55 89 22% 117 34%
55< Alkaline phosphatase ≤65 73 18% 77 22%
65< Alkaline phosphatase ≤80 119 29% 99 28%
80< Alkaline phosphatase 126 31% 55 16%
Missing 1 2
Bilirubin (mg/dL) 407 0.1–2.8 0.7 (0.4) 351 0–2.8 0.7 (0.4)
Bilirubin ≤ 0.5 144 35% 114 32%
0.5 < Bilirubin ≤ 0.7 120 29% 94 27%
0.7 < Bilirubin ≤ 0.9 69 17% 73 21%
0.9 < Bilirubin 74 18% 70 20%
Missing 1 1
1Difference between retrospective and prospective era donors was significant only for alkaline phosphatase (p < 0.0001).
117 IU/L), retrospective and prospective era study sub-
jects were combined for some subsequent analyses. Out
of the 20/760 (2.6%) aborted procedures, 12/408 (2.9%)
occurred in the retrospective era and 8/352 (2.3%) in the
prospective era. Reasons for aborting the procedure were
similar in both eras and included unexpected observations
during either donor or recipient procedures. One retrospec-
tive era aborted donor had a bile leak, bacterial infection
and localized intraabdominal abscess, each of which was
Clavien grade 2. The 20 aborted donors were not included
in the subsequent analyses.
Intraoperative donor characteristics are shown in Table 2B
for the 740 individuals who underwent a completed donor
lobectomy. Differences between the retrospective and
prospective cohorts were significant for remnant liver
weight (on average 28 g higher in the retrospective era;
p = 0.015), units of transfused blood (0.2 units more in the
retrospective era; p < 0.0001), intraoperative hypotension
(more common in the prospective era; p < 0.0001), oper-
ative time (97 min longer for retrospective era donors; p <
0.0001) and donor lobe resected (more left lobe donors in
the prospective era; p = 0.002).
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Table 2B: Intraoperative characteristics of adult living liver donors who underwent graft resection1
Retrospective Era donors (N = 396) Prospective Era donors (N = 344 )
Characteristic N Range Mean (SD) or percent N Range Mean (SD) or percent
Remnant liver weight2,3 (grams) 393 169–1152 576 (156) 344 195–1605 548 (152)
Weight ≤ 470 99 25% 110 32%
470 < Weight ≤ 570 87 22% 91 26%
570 < Weight ≤ 660 96 24% 78 23%
660 < Weight 111 28% 63 18%
Missing 3 0
Units of transfused blood3 392 0–4 0.4 (0.8) 339 0–6 0.2 (0.6)
0 272 69% 284 84%
1 84 21% 48 14%
2 26 7% 3 <1%
3 6 2% 3 <1%
4 4 1% 0 0%
6 0 0% 1 <1%
Missing 4 5
Hypotension3 (< 100 mmHg systolic)
Yes 89 23% 162 48%
Total duration (minutes) 3–455 62 (68) 5–420 73 (77)
No 291 77% 180 52%
Missing 16 2
Operative time3 (minutes) 333 236–930 457 (133) 340 185–770 360 (111)
Time ≤ 320 44 13% 137 40%
320 < Time ≤ 380 76 23% 96 28%
380 < Time ≤ 480 82 25% 57 17%
480 < Time 131 39% 50 15%
Missing 63 4
Donor lobe resected3
Right 387 98% 320 93%
Left 9 2% 24 7%
1Donors who successfully donated (Retrospective Era: N = 395, Prospective Era: N = 343) and those with graft resected but not
transplanted into the intended recipient (Retrospective Era: N = 1, Prospective Era: N = 1).
2Remnant liver weight was obtained from imaging at evaluation (Retrospective Era: 69%, Prospective Era: 98%) or 0.4 × donor Standard
Liver Volume (Retrospective Era: 30%, Prospective Era: 2%).
3Differences between Retrospective and Prospective Era donors were significant for remnant liver weight (p = 0.015), units of transfused
blood (p < 0.0001), hypotension (p < 0.0001), operative time (p < 0.0001) and donor lobe resected (p = 0.002).
Number of complications and severity grading of
complications
Complication type, number and highest Clavien grade
(among those with multiple complications of a given type)
are delineated in Table 3 for the entire observational co-
hort. One or more complications were experienced by 296
donors (40%), resulting in an aggregate of 557 recorded
complications; 140 donors (19%) experienced multiple
complications. For donors who experiencedmore than one
occurrence of a given complication, the highest Clavien
grade of that complication type was used.
Among retrospective era donors, there were four Clavien
grade 3 complications, one each with intraabdominal ab-
scess and bowel obstruction and two with complex her-
nias. In addition, there were three donor deaths (grade 4).
One donor died as a result of sepsis and multiorgan failure
in the perioperative period and two donors died relatively
late following donation (1.8 and 1.9 years) from psycholog-
ical complications (one accidental drug overdose and one
suicide) (5). Among prospective era donors, there was one
Clavien grade 3 complication (wound dehiscence) and no
Clavien grade 4 complications. There was no significant
association between the distribution of Clavien grades and
the number of complications each donor experienced, al-
though it was notable that grade 4 complications occurred
only in donors with >4 complications (Figure 1).
Probability of donor complications
Unadjusted probabilities of selected short-term (by 90
days) and long-term (by 6 years) complications are re-
ported by study era (Table 4). Aside from pleural ef-
fusions, other short-term complications, including infec-
tion, bile leak, neuropraxia, reexploration and prolonged
ileus, all occurred with similar probabilities in the two
eras. Pleural effusion may have been more completely
ascertained among prospective era donations. The prob-
abilities of long-term complications (hernia, psychological
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Table 3: Type and severity of complications (intraoperative/postoperative) of donors with nonaborted procedure according to highest
Clavien grade (n = 740)1
Highest Clavien grade
Complication Number of complications Number of donors 1 2 3 4
Intraoperative
Intraoperative injury2 4 4
Intraoperative other complications2 11 11
Biliary
Bile leak/biloma 62 60 25 35
Biliary stricture 5 5 1 4
Abdominal
Intraabdominal bleeding 7 7 2 5
Upper/lower GI bleeding 2 2 2
Intraabdominal abscesses 9 9 1 7 1
Ileus 25 25 13 12
Bowel obstruction 13 12 3 8 1
Incisional hernia 54 49 10 37 2
Wound dehiscence 6 6 3 2 1
Unplanned reexploration 20 20 1 19
Clostridium difficile colitis 2 2 2
Cardiopulmonary
Pneumothorax 6 6 5 1
Pleural effusion 83 81 64 17
Pulmonary edema 15 15 12 3
Respiratory arrest 1 1 1
Aspiration 2 2 1 1
Pulmonary embolism 7 7 2 5
Hepatic
Encephalopathy/hepatic coma 2 2 1 1
Ascites 21 21 17 4
Liver failure 0 0
Hepatic artery thrombosis 0 0
Portal vein thrombosis 4 4 2 2
Inferior vena cava thrombosis 3 3 3
Other
Deep vein thrombosis 6 6 6
Neuropraxia 24 24 19 5
Infections2 112 98 25 72 1
Psychological difficulties2 51 42 23 17 2
Total 557 2963 232 269 5 3
1Donors who successfully donated (Retrospective: N = 395, Prospective: N = 343) plus those with graft resected but not transplanted
into the intended recipient (Retrospective: N = 1, Prospective: N = 1).
2Some or all instances of this complication type were not graded individually.
3Total is less than sum of individual rows because 140 donors had more than 1 complication.
complications and bowel obstruction) were also similar in
the two eras. The overall probabilities of any complication
by 6 years were 0.45 for retrospective era donors and 0.51
for prospective era donors (p = 0.84).
Among the combined cohort of retrospective and prospec-
tive era subjects, the majority of first occurrences of in-
fections, pleural effusions, bile leaks, neuropraxia, reex-
plorations and prolonged ileus were within the first few
weeks after donation (Figure 2). However, a number of
complications first occurred many months or even years
after donation. Hernia, bowel obstruction and psycholog-
ical complications first developed as late as 5 to 6 years
following donation. Up to 7% of donors first experienced
individual types of complications more than 1 year after
donation.
Independent predictors of donor complications
Multivariable Cox regression models were fitted to test
potential predictors of a first complication of any type, and
also specifically of bile leak, hernia and infection. There
was a significant association of transfusion requirement
with the development of a first complication of any type
(HR = 1.38 per unit; p < 0.0001) and specifically with
the occurrence of bile leak (HR = 1.55; p < 0.0001) and
infection (HR = 1.40; p = 0.0011) (Table 5). In addition
to transfusion, intraoperative hypotension was associated
with a 48% higher risk of any complication (p = 0.0013),
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Figure 1: Distribution of Clavien grades by number of compli-
cations per person.
and higher predonation serum bilirubin was associated
with a lower risk of any complication (HR= 0.59 permg/dL;
p = 0.0061). The only additional significant predictor of
bile leak was body weight (HR = 1.22 per 10 kg; p =
0.0192). Older age, male gender and higher BMI were in-
dependently significant predictors of hernia formation. No
other covariates among those tested (listed in methods)
were significant predictors of these outcomes. In particu-
lar, when added to themultivariable models, neither center
experience nor year of donation (continuous or by trend
test using 3-year intervals) were significantly associated
with the risk of complications.
A test of the statistical interaction between units of trans-
fused blood and intraoperative hypotension was not signifi-
cant in the model for any complications. Thus, hypotension
did not appear to potentiate the adverse effect of trans-
fused blood, or vice versa. We also tested the potential
Figure 2: Cumulative probability of selected complication
after hepatic lobe donation.
interaction of gender and BMI in the time-to-hernia model;
this interaction was not significant.
The number of left lobe donors (n = 33) precluded exhaus-
tive covariate examination. Nonetheless, when tested in a
single-variable Cox model, the unadjusted risk of any com-
plication was significantly higher for left lobe donors (HR =
1.60; 95%CI 0.99–2.56; p= 0.05). When added to the final
multivariable Cox model, left lobe donation was unexpect-
edly associated with a higher risk of complications (HR =
1.55; 95% CI 0.96–2.51; p = 0.08), but this result did not
reach the traditional level of statistical significance.
Resolution of complications
Analysis of the course of complications from onset to res-
olution is depicted in Figure 3. Over a follow-up period
up to 9 years, 95% of complications were resolved and
the vast majority were resolved by 3 months postdona-
tion (Figure 3A). Complication types that presented later
postdonation (e.g., psychological and hernia) also tended
to take longer to resolve (Figure 3B). Several cases of
neuropraxia took more than 1 year to resolve. The prob-
ability of complete resolution within 1 year after diagno-
sis was only 75% for hernia and 42% for psychological
Table 4: Number of donors with selected complications and associated Kaplan–Meier estimates of the probabilities of occurrence by 90
days (short-term) or 6 years (long-term) in the retrospective and prospective eras
Retrospective Era (n = 396) Prospective Era (n = 344)
Complication N Probability at 90 days N Probability at 90 days Log-rank p-value
Short-term (within 90 days)
Infection 55 0.15 43 0.13 0.45
Bile leak / Biloma 36 0.09 24 0.07 0.25
Pleural effusion 24 0.06 57 0.17 <0.001
Neuropraxia 17 0.04 7 0.02 0.08
Reexploration 13 0.03 7 0.02 0.28
Prolonged ileus 11 0.03 14 0.04 0.34
N Probability at 6 years N Probability at 6 years
Long-term (within 6 years)
Any complication 158 0.45 138 0.51 0.84
Hernia 26 0.11 23 0.16 0.56
Psychological 23 0.09 19 0.07 0.71
Bowel obstruction 6 0.02 6 0.03 0.55
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Table 5: Multivariable Cox models testing predictors of any complication, bile leak, hernia, and infection. Time to first complication was
modeled1
Outcome Predictors HR 95% CI p-value
Any Bilirubin (per mg/dL) 0.59 0.41–0.86 0.006
Complication Units of transfused blood (per unit) 1.38 1.21–1.61 <0.001
Intraoperative hypotension 1.48 1.17–1.88 0.001
Bile leak Weight (per 10 kg) 1.22 1.03–1.43 0.019
Units of transfused blood (per unit) 1.55 1.25–1.92 <0.001
Hernia Age at donor evaluation (per 10 yrs) 1.41 1.08–1.92 0.01
Sex: male vs. female 1.82 1.00–3.33 0.05
Body mass index (per 5 kg/m2) 1.82 1.27–2.61 0.001
Infection Units of transfused blood (per unit) 1.40 1.15–1.72 0.001
HR = hazard ratio; CI = confidence interval
1The complete list of variables tested in each of the models is detailed in the Methods section.
complications, although both probabilities increased with
continued follow-up time.
Discussion
In 2008, we reported that in a retrospective cohort of 396
LLD (387 right and 9 full left lobes), 38% developed at
least one complication, the vast majority within the first
year (1). In 2010, the Toronto group reported that in a retro-
spective single center experience of 202 right lobe donors
with a minimum follow-up of 12 months, 40% developed
complications within the first year (6). Also in 2010, the Ky-
oto group updated their previously published experience
with LLD complications (7). A retrospective single-center
review of 500 right lobe donors with a median follow-up
period of 36.5 months revealed that 44% experienced at
least one complication within the follow-up period. In the
current study, we have markedly extended the duration
of follow-up in the retrospective era donors and include
an additional 352 donors whose procedures occurred in
the prospective era. In total, this represents the complete
experience with LLD at these nine centers over a nearly
12-year period. We now report that among 740 LLD (707
right lobes), 39% developed at least one complication in
the first year, an incidence strikingly similar to and confirm-
ing our prior experience and that of others. We have also
confirmed that increasing center experience is not asso-
ciated with a reduction in donor complications. Therefore,
we propose that 40% can be considered a fairly definitive
assessment of the risk of complications in the first year
following live donor right lobectomy. Regarding the sever-
ity of these complications, we had previously reported that
2.8% of patients had Clavien grade 3 or 4 complications
(1). Using a slight modification of the Clavien classification
in which grade 4 included residual disability or death, the
Toronto group (6) reported that out of 202 donors, 15.8%
of patients had a grade 3 and none had a grade 4 compli-
cation. The Kyoto group (7), using a 5-tier modification of
the Clavien system, reported that in 500 LLD (right lobe),
17% developed >grade 3 complications (consistent over 3
eras) with 1/500 grade 5 (death). Using the same grading
system, the Pittsburgh group (8) reported that among the
121 LLD (right lobectomy), 10.7% of patients developed
>grade 3 complications (no grade 5). Our current combined
A2ALL study shows that 8/740 LLD (1.1%) developed a
grade 3 (residual disability, n = 5) or grade 4 (liver failure
or death, n = 3), 7/396 (1.8%) in the retrospective era and
1/344 (0.3%) in the prospective era. The Kyoto and Pitts-
burgh groups used versions of the Clavien system that did
not specifically capture residual disabilities. Based on the
Toronto and A2ALL experience, the combined risk of resid-
ual disability, liver failure or death following LLD (0/202 and
8/740, respectively), is approximately 1%. We have previ-
ously defended our use of the 4-tier Clavien system (9).
Our current study also demonstrates that 20/760 (2.6%)
Figure 3: (A) Time to resolution of
all complications. [Inset in A – magni-
fication of first 12 months]. (B) Time to
resolution for specific complications.
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procedures were aborted intraoperatively (2.9% and 2.3%
in retrospective and prospective cohorts prospectively).
The Toronto group has reported 4.9% (12/252) aborted pro-
cedures (10). Thus, we consider that 2%–5% represents
the risk of aborted LLD.
A major aim of our study was to evaluate predictors as-
sociated with postdonation complications. The Pittsburgh
group identified BMI ≥ 30 and macrovesicular steatosis
as significant risk factors for the development of grade 4a
complications (8). The Kyoto group found donor age and
prolonged operative time to be associated with any com-
plication and with biliary complications, but gender, BMI,
and blood loss were not significant risk factors in a limited
analysis (7). We now confirm our previous observation,
that blood transfusion is associated with a significantly
higher risk of complication, and specifically of bile leaks
and infection (1). In our current study, each unit of trans-
fused blood was associated with a 38% to 55% higher
risk of complication. Intraoperative hypotension (systolic
blood pressure <100 mm Hg) was associated with an
overall higher risk of complications, independent of the
requirement for blood transfusions. Donors with higher
body weight were at significantly higher risk of bile leak;
each increment of 10 kg in body weight increased the
risk by 22%. Risk factors for incisional hernia formation
included older age, male gender and higher BMI, each of
which has been observed in populations of general surgi-
cal patients undergoing open abdominal procedures (11).
Baseline predonation laboratory studies have had inconsis-
tent associations with donor complications. In the current
study, we failed to confirm our prior finding that higher lev-
els of alkaline phosphatase were associated with a higher
risk of complications. However, higher predonation serum
bilirubin was surprisingly associated with a lower risk of de-
velopment of complications. As with alkaline phosphatase,
the vast majority of serum bilirubin levels fell within the nor-
mal range. A biological basis for these associations is not
obvious.
Previous studies have focused principally on the develop-
ment of complications within the first year following dona-
tion. We had previously reported that 46% of all compli-
cations occurred during the initial hospitalization (1). The
Toronto group focused their analyses on complications
within 30 days of donation and between 30 days and 1-
year postdonation (6), but noted one keloid, one incisional
hernia and one bowel obstruction that presented between
1 and 5 years postdonation. The Pittsburgh group did not re-
port long-term complications (8). The Kyoto report spanned
three empirical eras but made little attempt to analyze long-
term complications (7). Our current study demonstrates
that certain complications (hernia, bowel obstruction and
psychological complications) may develop as late as 5 or
more years after donation. A novel feature of the current
report is the analysis of the time to resolution of post-
donation complications, starting from their time of onset.
Nearly 80% of complications resolved by 3 months. How-
ever, some complications took many years to resolve or
remained unresolved as long as 3 to 5 years after pre-
sentation. The probabilities of resolution by 1 year after
diagnosis were only 75% and 42% for hernias and psycho-
logical complications, respectively. This is especially impor-
tant since these same types of complications tended to
occur later postdonation. In contrast, neuropraxia, which
developed immediately after donation, took as long as 3
years to resolve. Of interest, with longer follow-up, some
complications initially defined as Clavien grade 3 (residual
disability at the time of recording) eventually resolved and
were downgraded to 2, explaining the discrepancy in the
number of grade 3 complications between our previous
and current reports. This was true for several cases of neu-
ropraxia. The exact proportion of grade 3 complications that
eventually resolve over time and are therefore downgraded
to grade 2 is unclear, and while this may add confusion to
the assessment of donor morbidity, it highlights the need
for longer term follow-up and underlines the significance
of the current study. We did not observe any examples of
upgrading over time.
We should note that since the current analysis, two well
publicized donor (right lobectomy) deaths have occurred in
the US. One of these occurred at a center that participated
in the A2ALL study, on which we currently report, but the
study was closed for enrollment at the time of donor death
and therefore it is not included in the analysis. The other
donor death occurred at a nonparticipating center. Both
centers were among the most experienced adult LLD in
the US at the time of these events. Therefore, although
not part of our analysis, we believe that these deaths war-
rant mention to prevent an erroneous interpretation of a
decrease in grades 3 and 4 complications between the
retrospective and prospective cohorts.
Limitations of our study include limited data for some
donors who may have sought treatment elsewhere, and
the possibility of under-ascertainment of retrospectively
assessed complications. Although we collected data on
29 specific complications generated by consensus among
the study investigators, we did not include an ‘other’ cate-
gory for rare or unexpected complications. All centerswere
monitored annually, but only approximately 10% of records
were audited for accuracy of reporting. Over the course of
the study, these audits uncovered a few new complica-
tions, suggesting that complications may be slightly un-
derestimated. In addition, the exact nature of donor work
up was not prescribed by the study and it is certainly
possible that participating centers used varying inclusion
and exclusion criteria for donors, and that these may have
changed over the period of study. Finally, our observations
regarding the relative risk of complications for left versus
right lobe donation are inconsistent with that of others (7),
most likely as a result of the small number of left lobe
donors in our cohort. We believe that all the limitations
described above could have only a modest effect on our
results.
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From this longitudinal observational cohort of 740 com-
pleted hepatic lobe donations in the multicenter A2ALL
consortium, we can draw several important conclusions:
(1) the incidence and severity of LLD complications arewell
defined and do not appear to change over time (40% over-
all incidence of complications, 1% incidence of residual
disability, liver failure or death and 2%–5% risk of aborted
donation); (2) there do not appear to be any significant
risks associated with LLD complications not previously
identified; (3) the impetus to further compile and regis-
ter LLD complications specifically for the purpose of as-
sessing general donor risk should take into consideration
our first two conclusions. We believe that any further in-
vestigation should focus on assessing the relative risk of
evolving LLD approaches that may alter the risk profile
and (4) we have found that longer follow-up (>1 year) al-
lows for a better understanding of the natural history of
LLD complications, including late complications and time
to resolution. Therefore, we believe that the current study
will serve as a comprehensive report to inform decision
making by potential donors and their caregivers, and as a
benchmark against which the effectiveness of future inter-
ventions or strategies to reduce donor complications can
be measured.
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